Recent advances in gastrointestinal cancers
- PMID: 34366620
- PMCID: PMC8326255
- DOI: 10.3748/wjg.v27.i28.4493
Recent advances in gastrointestinal cancers
Abstract
Gastrointestinal cancers occur in a total of eight different locations, each of them with a different standard of care. This article is not an exhaustive review of what has been published in 2020. We have concentrated on the thirteen phase III randomized studies that are practice-changing. All these studies are oral presentations which have been given in one of the four major oncology congresses, namely American Society of Clinical Oncology (ASCO), ASCO gastrointestinal (GI), European Society of Medical Oncology (ESMO) and ESMO-GI. We provide a concise view of these major trials and their main outcomes, and put these results into context.
Keywords: Gastric cancer; Gastrointestinal; Gastrointestinal cancers; Immunotherapy; Practice changing trials.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: No conflict of interest.
Figures



Similar articles
-
Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting.J Gastrointest Cancer. 2023 Jun;54(2):672-676. doi: 10.1007/s12029-022-00849-5. Epub 2022 Jul 19. J Gastrointest Cancer. 2023. PMID: 35856132 Review.
-
[ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].Z Gastroenterol. 2016 Feb;54(2):167-72. doi: 10.1055/s-0041-111632. Epub 2016 Feb 8. Z Gastroenterol. 2016. PMID: 26854837 German.
-
[ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006].Z Gastroenterol. 2006 Oct;44(10):1065-72. doi: 10.1055/s-2006-927142. Z Gastroenterol. 2006. PMID: 17063436 German.
-
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].Z Gastroenterol. 2018 Apr;56(4):384-397. doi: 10.1055/s-0044-101757. Epub 2018 Apr 11. Z Gastroenterol. 2018. PMID: 29642252 German.
-
Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.Ann Oncol. 2017 Dec 1;28(12):3022-3027. doi: 10.1093/annonc/mdx547. Ann Oncol. 2017. PMID: 29045525 Review.
Cited by
-
Chitosan and Cyclodextrins-Versatile Materials Used to Create Drug Delivery Systems for Gastrointestinal Cancers.Pharmaceutics. 2023 Dec 27;16(1):43. doi: 10.3390/pharmaceutics16010043. Pharmaceutics. 2023. PMID: 38258054 Free PMC article. Review.
-
The Role of Selected Serpins in Gastrointestinal (GI) Malignancies.J Clin Med. 2022 Oct 21;11(20):6225. doi: 10.3390/jcm11206225. J Clin Med. 2022. PMID: 36294546 Free PMC article. Review.
-
Targeted ferritinophagy in gastrointestinal cancer: from molecular mechanisms to implications.Arch Toxicol. 2024 Jul;98(7):2007-2018. doi: 10.1007/s00204-024-03745-y. Epub 2024 Apr 11. Arch Toxicol. 2024. PMID: 38602537 Review.
-
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.Mol Cancer. 2024 Oct 23;23(1):237. doi: 10.1186/s12943-024-02151-3. Mol Cancer. 2024. PMID: 39443938 Free PMC article. Review.
-
Comparative analysis of tumor biology and prognosis in mucinous and signet-ring cell colon cancers versus classical adenocarcinoma.Front Physiol. 2023 Jul 31;14:1199211. doi: 10.3389/fphys.2023.1199211. eCollection 2023. Front Physiol. 2023. PMID: 37588851 Free PMC article.
References
-
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK ToGA Trial Investigators. Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. - PubMed
-
- Safran H, Winter KA, Wigle DA, DiPetrillo TA, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick MB, Kachnic LA, Seaward SA, Mamon HJ, Pardo DAD, Anderson CM, Shen X, Sharma AK, Katz AW, Salo JC, Leonard KL, Crane CH. Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. J Clin Oncol. 2020;38:4500–4500. - PMC - PubMed
-
- Hulshof MCCM, Geijsen D, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens J, Sangen MVD, Jeene P, Reinders J, Henegouwen MI van B, Hooft JE van, Laarhoven HWMV, Gaast AVD. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol. 2020;38:281–281. - PubMed
-
- Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–1168. - PubMed
-
- Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab vs chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–1517. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources